Cited by 41Schizophrenia research and treatmentFunctional Brain Connectivity StudiesNeurotransmitter Receptor Influence on Behavior

Antipsychotic Drugs Alter Functional Connectivity between the Medial Frontal Cortex, Hippocampus, and Nucleus Accumbens as Measured by H215O PET

Open access
Bolding, Mark S., White, David M., Hadley, Jennifer A., Weiler, Martin, Holcomb, Henry H., Lahti, Adrienne C.·2012·Frontiers in Psychiatry

Abstract

To evaluate changes in functional connectivity as a result of treatment with antipsychotic drugs (APDs) in subjects with schizophrenia (SZ), we identified a limited number of regions that have been implicated in the mechanism of action of APDs and that are part of a neuronal network known to be modulated by dopamine (DA). These regions consisted of the nucleus accumbens (NAcc), the hippocampus (Hip), and the medial frontal cortex (MFC). SZ participants were blindly randomized into a haloperidol treatment group (n = 12) and an olanzapine treatment group (n = 17). Using PET with 15O, we evaluated changes in functional connectivity between these regions during rest and task performance at three treatment time points: (1) at baseline, after withdrawal of all psychotropic medication (2 weeks), (2) after 1 week on medication, and (3) after 6 weeks on medication. Results from the two treatment groups were combined during analysis to investigate the common effects of APDs on functional connectivity. We found that the functional connectivity between MFC and NAcc significantly increased at week one, and then significantly decreased from week one to week 6. The functional connectivity between MFC and Hip significantly decreased at week one and week 6 relative to baseline. Critically, the strength of the functional connectivity between the MFC and Hip after 1 week of treatment was predictive of treatment response. This pattern of changes may represent an important biomarker for indexing treatment response. The regulation by APDs of the balance between prefrontal and limbic inputs to the striatum may be crucial to restoring adaptive behavior.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fpsyt.2012.00105

Cites

62 of 65 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Lahti A. C. Lahti R. A. Tamminga C. A. (1996). “New neuroleptics and experimental antipsychotics: future roles,” in The New Pharmacotherapy of Schizophrenia, ed. Breier A. (Washington: APA Press), 57– 87
  2. Tamminga C. Dannals R. F. Frost J. Wong D. Wagner H. N. (1993). “Neuroreceptor and neurochemistry studies with positron emission tomography in psychiatric illness: promise and progress,” in Review of Psychiatry, eds Oldham J. Riba M. Tasman A. (Washington, DC: American Psychiatric Press), 487– 510

Cited by

Sorted by citations

Authors
Bolding, M. S., White, D. M., Hadley, J. A., Weiler, M., Holcomb, H. H., & Lahti, A. C.
Affiliations
  • University of Alabama at Birmingham (US)
  • University of Maryland, Baltimore (US)
Corresponding author
Lahti, Adrienne C.
Venue
Frontiers in Psychiatry
Published
2012
Volume
3
Pages
105-105
ISSN
1664-0640 (ISSN-L)
OpenAlex
W1967938101
Cited by
41
References
64
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 4 · 2013: 1
FWCI
2.74
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Psychiatry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institute of Mental Health (R01MH102951, R01MH057971)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Functional Brain Connectivity Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
antipsychotic drugs, schizophrenia, functional connectivity, medial frontal cortex, hippocampus, nucleus accumbens, haloperidol, olanzapine, treatment response prediction, treatment response biomarkers, dopamine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review